Adding Itraconazole to AML Treatment
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether adding the antifungal drug itraconazole to standard AML treatment can improve outcomes. It is for adults with AML who are in fairly good health and do not have heart failure or severe kidney problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML).
- You must be 18 years or older.
- Your daily activity level should be fairly good (ECOG 0-2), meaning you are up and about at least half the day.
- You cannot have any other cancer besides leukemia.
- You cannot have a known allergy to itraconazole or a history of alcohol use.
- You cannot have chronic heart failure, severe dehydration, or severe kidney problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a maintenance treatment called 'ITIVA' for people with acute myeloid leukemia (AML) who have achieved remission after initial chemotherapy and consolidation therapy. The goal is to see if this treatment helps keep the leukemia from coming back.
This trial tests whether using a targeted antifungal medicine (aimed at PTX3) can better prevent serious fungal infections in adults with AML or a related bone marrow disease who will have very low neutrophils. It may help lower the risk of dangerous infections during intensive chemotherapy hospital stays.
This trial tests a combination of two drugs, SA and X, for people who have just been diagnosed with acute myeloid leukemia (AML) and have not yet received treatment (except hydroxyurea to lower white blood cells). The goal is to see if the combination works better than standard care.
This Phase 3 trial tests whether adding gemtuzumab to standard chemotherapy helps people with newly diagnosed, favorable-intermediate AML reduce “MRD” (very small remaining leukemia cells). If MRD levels drop more, it may lower the chance of relapse.
This trial tests whether adding ivosidenib to an oral chemotherapy pill (azacitidine) helps prevent relapse in adults over 55 who have a specific IDH1 gene mutation and whose acute myeloid leukemia is in remission after intensive chemo.
This trial tests a combination of three drugs – venetoclax, cytarabine, and metformin – for adults with AML who cannot receive standard high-dose chemotherapy. It aims to see if this gentler mix can help control the leukemia with fewer side effects.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.